"I am grateful to our long-standing customer Takeda for its flexibility, which enables us to provide the world with much-needed COVID-19 vaccines," said IDT Biologika Chief Executive Juergen Betzing.
Dessau-based IDT is already producing AstraZeneca's COVID-19 vaccine, as well as developing its own shot against the coronavirus.
BERLIN: Germany's IDT Biologika said on Monday it would start producing Johnson & Johnson's single shot COVID-19 vaccine using capacity previously reserved by Japan's Takeda.
IDT said it will fill and package the COVID-19 shot, which was approved by the European Union's drug regulator last week, for a period of three months after which it will resume making Takeda's TAK-003 dengue vaccine.
"I am grateful to our long-standing customer Takeda for its flexibility, which enables us to provide the world with much-needed COVID-19 vaccines," said IDT Biologika Chief Executive Juergen Betzing.
Dessau-based IDT is already producing AstraZeneca's COVID-19 vaccine, as well as developing its own shot against the coronavirus.
Comments
Comments are closed for this article.